Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression

Atherosclerosis

Volumn 246, Issue , 2016, Pages 13-20

  Bhatia, Lokpal ^a,b   Scorletti, Eleonora ^a,b   Curzen, Nicholas ^b   Clough, Geraldine F ^a,b   Calder, Philip C ^a,b   Byrne, Christopher D ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Atherosclerosis; Cardiovascular disease; Carotid intima media thickness; Fatty acids; Non alcoholic fatty liver disease; Omega 3

Indexed keywords

CYTOKERATIN 18; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PLACEBO; BIOLOGICAL MARKER; DRUG COMBINATION;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; B SCAN; BODY WEIGHT; CARDIOVASCULAR RISK; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CAROTID ARTERY DISEASES; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; DUPLEX DOPPLER ULTRASONOGRAPHY; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; BIOMARKERS; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; ULTRASONOGRAPHY, DOPPLER, DUPLEX;

EID: 84952673841     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.12.028     Document Type: Article

References (37)

1. Browning J.D., Szczepaniak L.S., Dobbins R., Nuremberg P., Horton J.D., Cohen J.C., Grundy S.M., Hobbs H.H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
2. Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur. Heart J. 2012, 33:1190-1200.
3. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
4. Bots M.L., Evans G.W., Riley W.A., Grobbee D.E. Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view. Stroke 2003, 34:2985-2994.
5. Duivenvoorden R., de Groot E., Stroes E.S., Kastelein J.J. Surrogate markers in clinical trials-challenges and opportunities. Atherosclerosis 2009, 206:8-16.
6. Gastaldelli A., Kozakova M., Hojlund K., Flyvbjerg A., Favuzzi A., Mitrakou A., Balkau B. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology 2009, 49:1537-1544.
7. Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Hodson L., Moyses H.E., Calder P.C., Byrne C.D., Study W. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome study. Hepatology 2014, 60:1211-1221.
8. Sekikawa A., Curb J.D., Ueshima H., et al. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J. Am. Coll. Cardiol. 2008, 52:417-424.
9. Cawood A.L., Ding R., Napper F.L., Young R.H., Williams J.A., Ward M.J., Gudmundsen O., Vige R., Payne S.P., Ye S., Shearman C.P., Gallagher P.J., Grimble R.F., Calder P.C. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 2010, 212:252-259.
10. Hjerkinn E.M., Abdelnoor M., Breivik L., Bergengen L., Ellingsen I., Seljeflot I., Aase O., Ole Klemsdal T., Hjermann I., Arnesen H. Effect of diet or very long chain omega-3 fatty acids on progression of atherosclerosis, evaluated by carotid plaques, intima-media thickness and by pulse wave propagation in elderly men with hypercholesterolaemia. Eur. J. Cardiovasc Prev. Rehabil. 2006, 13:325-333.
11. Scorletti E., Bhatia L., McCormick K.G., Clough G.F., Nash K., Calder P.C., Byrne C.D., Investigators W.T. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemp. Clin. Trials 2014, 37:301-311.
12. Ratziu V., Bellentani S., Cortez-Pinto H., Day C., Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 2010, 53:372-384.
13. Shen J., Chan H.L., Wong G.L., Chan A.W., Choi P.C., Chan H.Y., Chim A.M., Yeung D.K., Yu J., Chu W.C., Wong V.W. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Aliment. Pharmacol. Ther. 2012, 36:1057-1066.
14. Mehta S.R., Thomas E.L., Bell J.D., Johnston D.G., Taylor-Robinson S.D. Non-invasive means of measuring hepatic fat content. World J. Gastroenterol. 2008, 14:3476-3483.
15. Stein J.H., Korcarz C.E., Hurst R.T., Lonn E., Kendall C.B., Mohler E.R., Najjar S.S., Rembold C.M., Post W.S. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media thickness task Force. Endorsed by the Society for vascular Medicine. J. Am. Soc. Echocardiogr. 2008, 21:93-111. American Society of Echocardiography Carotid Intima-Media Thickness Task F, quiz 189-190.
16. Saravanan P., Davidson N.C., Schmidt E.B., Calder P.C. Cardiovascular effects of marine omega-3 fatty acids. Lancet 2010, 376:540-550.
17. Dai X.W., Zhang B., Wang P., Chen C.G., Chen Y.M., Su Y.X. Erythrocyte membrane n-3 fatty acid levels and carotid atherosclerosis in Chinese men and women. Atherosclerosis 2014, 232:79-85.
18. Lonn E.M., Bosch J., Diaz R., et al. Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care 2013, 36:2466-2474.
19. Wang C., Harris W.S., Chung M., Lichtenstein A.H., Balk E.M., Kupelnick B., Jordan H.S., Lau J. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am. J. Clin. Nutr. 2006, 84:5-17.
20. Kromhout D., Yasuda S., Geleijnse J.M., Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?. Eur. Heart J. 2012, 33:436-443.
21. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 2008, 49:600-607.
22. Bhatia L.S., Curzen N.P., Byrne C.D. Nonalcoholic fatty liver disease and vascular risk. Curr. Opin. Cardiol. 2012, 27:420-428.
23. Chambless L.E., Folsom A.R., Davis V., Sharrett R., Heiss G., Sorlie P., Szklo M., Howard G., Evans G.W. Risk factors for progression of common carotid atherosclerosis: the atherosclerosis risk in communities study, 1987-1998. Am. J. Epidemiol. 2002, 155:38-47.
24. Lakka T.A., Lakka H.M., Salonen R., Kaplan G.A., Salonen J.T. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men. Atherosclerosis 2001, 154:497-504.
25. Kang S., Wu Y., Li X. Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis. Atherosclerosis 2004, 177:433-442.
26. Markus R.A., Mack W.J., Azen S.P., Hodis H.N. Influence of lifestyle modification on atherosclerotic progression determined by ultrasonographic change in the common carotid intima-media thickness. Am. J. Clin. Nutr. 1997, 65:1000-1004.
27. Feldstein A.E., Wieckowska A., Lopez A.R., Liu Y.C., Zein N.N., McCullough A.J. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
28. Vuppalanchi R., Jain A.K., Deppe R., Yates K., Comerford M., Masuoka H.C., Neuschwander-Tetri B.A., Loomba R., Brunt E.M., Kleiner D.E., Molleston J.P., Schwimmer J.B., Lavine J.E., Tonascia J., Chalasani N. Relationship between changes in serum levels of Keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2014, 12:2121-2130.
29. Tsutsui M., Tanaka N., Kawakubo M., Sheena Y., Horiuchi A., Komatsu M., Nagaya T., Joshita S., Umemura T., Ichijo T., Matsumoto A., Yoshizawa K., Aoyama T., Tanaka E., Sano K. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J. Clin. Gastroenterol. 2010, 44:440-447.
30. Targher G., Bertolini L., Padovani R., Rodella S., Zoppini G., Zenari L., Cigolini M., Falezza G., Arcaro G. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29:1325-1330.
31. Ekstedt M., Franzen L.E., Mathiesen U.L., Thorelius L., Holmqvist M., Bodemar G., Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
32. Soderberg C., Stal P., Askling J., Glaumann H., Lindberg G., Marmur J., Hultcrantz R. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
33. Byrne C.D., Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015, 62:S47-S64.
34. Karason K., Wikstrand J., Sjostrom L., Wendelhag I. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int. J. Obes. Relat. Metab. Disord. 1999, 23:948-956.
35. de las Fuentes L., Waggoner A.D., Mohammed B.S., Stein R.I., Miller B.V., Foster G.D., Wyatt H.R., Klein S., Davila-Roman V.G. Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. J. Am. Coll. Cardiol. 2009, 54:2376-2381.
36. Cooper J.N., Columbus M.L., Shields K.J., Asubonteng J., Meyer M.L., Sutton-Tyrrell K., Goodpaster B.H., DeLany J.P., Jakicic J.M., Barinas-Mitchell E. Effects of an intensive behavioral weight loss intervention consisting of caloric restriction with or without physical activity on common carotid artery remodeling in severely obese adults. Metabolism 2012, 61:1589-1597.
37. Musso G., Cassader M., Rosina F., Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55:885-904.